Background Hypogammaglobulinemia is common in Waldenström's macroglobulinemia (WM), and has been attributed to disease-related suppression. The etiology for this finding remains unclear, and has been speculated to be on the basis of tumor-induced suppression.
Design and Methods
We evaluated the incidence of IgA and IgG hypogammaglobulinemia in 207 untreated WM patients and addressed the associated clinicopathological findings, and impact of therapy. We also sequenced 8 genes (AICDA; BTK; CD40; CD154; NEMO, TACI, SH2D1A, UNG) implicated in immunoglobulin deficiency in 19 WM patients with IgA and/or IgG hypogammaglobulinemia.
Results
At baseline 63.3%, 58.0% and 49.3% of the 207 patients had abnormally low serum levels of IgA, IgG, or both. No association between IgA and IgG hypogammaglobulinemia and disease burden, serum IgM levels, B2M, IPSS score, or incidence of recurrent infections was observed, though presence of adenopathy and/or splenomegaly was associated with a lower incidence of hypogammaglobulinemia. Lower IgA and IgG levels were associated with disease progression in watch and wait patients. IgA and/or IgG levels remained abnormally low despite response to treatment, including complete remissions. A missense mutation in the highly conserved catalytic site of UNG was observed in a patient with hypogammaglobulinemia warranting further study of this pathway in WM.
Conclusions
IgA and IgG hypogammaglobulinemia is common in WM which persists despite therapeutic intervention and response. IgA and IgG hypogammaglobulinemia do not predict for recurrent infection risk in WM patients, though lower levels of serum IgA and IgG are associated with disease progression in WM patients on watch and wait. 1 This condition is considered to be lymphoplasmacytic lymphoma as defined by the REAL and WHO classification systems. 2, 3 Up to 20% of patients with WM appear to have a first degree relative with WM or related B-cell disorder suggesting a possible genetic predisposition to this rare disease. 4 Recurrent infections, particularly involving the respiratory tract are commonly observed among patients with WM, and may be related to the presence of IgA and IgG hypogammaglobulinemia. 5 The presence of hypogammaglobulinemia involving the uninvolved immunoglobulin has also been reported among other B-cell malignancies. 6, 7 The etiology for this finding remains unclear, and has been speculated to be on the basis of tumor-induced immunoparesis and host-mediated homeostatic regulation of uninvolved immunoglobulin production.
Little is also known about the impact of IgA and IgG immunoglobulin levels on infection risk in WM patients, who often present with respiratory tract infections,4 as well as the evolution IgA and IgG levels over the course of disease and following therapy in WM. As such, we evaluated the incidence of IgA and IgG hypogammaglobulinemia in 207 untreated WM patients and addressed the associated clinicopathological findings as well as disease course on IgA and IgG hypogammaglobulinemia. Additionally, we evaluated the impact of therapy, as well as clinical remission status on IgA and IgG immunoglobulin levels on 93 serially treated patients with WM.
Lastly, as part of these studies, we sequenced 8 genes often implicated in immunoglobulin deficiency disorders such as common variable immunodeficiency disorder (CVID), Hyper IGM syndrome (HIGM), and Xlinked agammaglobulinemia (XLA) in 19 patients with WM who demonstrated IgA and/or IgG deficiency.
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Design and Methods
To analyze the incidence of hypogammaglobulinemia in WM, serum immunoglobulin levels calculated by immunofixation were serially gathered from 207 previously untreated patients at their first clinic visit. This study was conducted in accordance with the Dana-Farber/Harvard Cancer Center institutional review board. All participants met the consensus panel definition for WM1 and were considered to have hypogammaglobulinemia if their uninvolved immunoglobulin levels were below the lower limit of our institutional normal range (i.e. <700 mg/dL and <70 mg/dL for IgG and IgA, respectively). As part of this analysis, we assessed the impact of patient age, sex, bone marrow disease infiltration with lymphoplasmacytic cells, adenopathy, splenomegaly, serum IgM levels as determined by immunonephelometry, complete blood counts, absolute lymphocyte count, β2-microglobulin, and prognostic score as assessed by the WM International Prognostic Scoring System 13 on presence or absence of IgA and IgG hypogammaglobulinemia. The impact of IgA and IgG hypogammaglobulinemia on the risk of recurring infections, defined as an infection occurring more than once in a year, was also assessed.
To delineate the impact of disease progression on uninvolved immunoglobulin levels over time, we followed the IgA and IgG levels in 102/207 patients who were placed in observation at their first visit, and who continued to have follow-up at our Institution. This included 60 patients who remained progression free, and 42 patients who eventually progressed during our follow-up period. To understand the impact of therapeutic intervention on uninvolved immunoglobulin levels, we also analyzed changes in IgA and IgG levels in a separate cohort of 93 patients who underwent treatment for WM and had immunoglobulin levels tested pre-therapy, post-therapy, and at least one month follow up after completion of all therapy. Outcomes for these patients were determined using consensus panel response criteria from the Third International Workshop on WM.
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Sequencing of CVID associated genes
DNA from peripheral blood mononuclear cells was obtained from 19 WM patients who demonstrated IgA and/or IgG hypogammaglobulinemia. Sequence analysis of the promoter, all exonic, and flanking intronic regions was performed for AICDA; BTK; CD40; CD154; NEMO, TACI, SH2D1A, UNG which are associated with the immunoglobulin deficiency disorders CVID, HIGM, and XLA. All sequencing studies were performed by Correlagen Diagnostics Inc. (Waltham, Massachusetts, USA) using CLIA approved diagnostic assays.
Biostatistics
Analysis of clinical data was performed by logistic regression analysis, ANOVA, and Spearman Rank Correlation analysis. All analyses were performed using SAS (SAS Institute, Cary NC, USA). Non-parametric testing was performed using a two-tailed Fisher's exact probability test (VassarStats). A p-value <0.05 was deemed to be significant in all studies.
Results
IgA and IgG hypogammaglobulinemia in WM
We first analyzed the prevalence of IgA and IgG hypogammaglobulinemia in newly diagnosed patients with WM. The median age of these patients was 60 (range 32-83 years) and the male to female ratio was 1.4. The median IgM was 2,910 (range 179-12,400 mg/dL) and the median bone marrow involvement with disease was 40% (range 5-95%). Of these patients, 131 (63.3%) and 120 (58.0%) patients 
Impact of IgA and IgG hypogammaglobulinemia on infection risk in WM
We next assessed the impact of presenting with IgA and IgG hypogammaglobulinemia on recurrent infection risk for 205 of the 207 WM patients for whom this data was available. The presence of IgA, IgG or both IgA and IgG hypogammaglobulinemia, even at lower cutoffs (i.e. IgA <30; IgG <300 mg/dL) did not predict for the occurrence of recurring infections, which were nearly all respiratory in nature, mainly <grade 2, and consisted of sinus (n=53; 25.85%), bronchial (n=16; 7.80%), unspecified upper respiratory tract (n=14; 6.83%), and pneumonic (n=7; 3.41%) infections (Table  1) .
Evolution of IgA and IgG hypogammaglobulinemia in WM
We next evaluated those untreated patients who did not demonstrate disease progression during the course of our follow-up. With a median follow-up of 26 (range 4-106 months), IgA and IgG levels remained stable for most patients. Twenty-eight of 60 (47%) patients demonstrated decreased IgA levels at baseline, while 32/60 (53%) of these patients were abnormally low at the end of follow-up; similarly 29/60 (48%) of patients demonstrated subnormal IgG levels at baseline, which remained unchanged at last follow-up (p=0.47 and 1.0, respectively). We also evaluated those untreated patients who eventually demonstrated disease progression during the course of our follow-up. With a median follow-up of 13 (range 4-144 months), 29/42 (69%) patients demonstrated decreased IgA levels at baseline, while 31/42 (74%) of these patients were abnormally low at the end of follow-up (p=0.63). Similarly, 27/42 (64%) of patients demonstrated decreased IgG levels at baseline, and 30/42 (71%) remained low at last follow-up (p=0.48). While comparison of the presence of IgA and/or IgG hypogammaglobulinemia between those patients who remained progression free and those who progressed did not demonstrate any significant differences (data not shown), the median level of serum IgA (45 vs. 72 mg/dL) and IgG (558 versus 716 mg/dL) was lower for patients who demonstrated disease progression versus those patients who remained progression free during the follow-up period, though was only significant for IgG (p=0.018).
Impact of therapy and response on IgA and IgG levels
To understand the impact of WM directed therapeutic intervention on uninvolved immunoglobulin levels, we analyzed changes in IgA and IgG levels in a cohort of 93 patients who underwent treatment for WM and whose baseline characteristics are depicted in Table 2 . The median age for these patients was 61 (range 43 -86 years), and the median pre-therapy IgM level and bone marrow disease burden were 3,730 (range 458 -12,400 mg/dL) and 40% (range 5-95%), respectively. Therapies for these patients included rituximab (n=3); fludarabine and rituximab (n=19); cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (Table 3) , including in those patients who had who had followup in excess of 1 (n=46), 2 (n=25), and 3 (n=8) or more years post-therapy (p=NS). Median serum IgM levels during this period declined from 3,730 (range 458-12,400 mg/dL) to 1,320 (23-5,650 mg/dL) at best response.
Lastly, we analyzed the impact of response quality on recovery of IgA and/or IgG immunoglobulin levels in this cohort. Eighty-one (87%) of the 93 patients demonstrated at least a minor response. Categorical responses for these patients were as follows: 9 complete (CR), 49 partial (PR; > 50% decrease in IgM), and 23 minor (MR; > 25% decrease in IgM) responses. No significant recovery in IgA and IgG levels was observed in any therapeutic response category during the course of follow-up, including among patients who attained a complete response (Table 4 ).
Sequencing of CVID associated genes
Sequence analysis of the promoter, all exonic, and flanking intronic regions for each gene was performed in 19 patients with WM who exhibited at baseline IgA (n=5), or both IgA and IgG (n=14) hypogammaglobulinemia. Sequencing studies demonstrated no novel variants in the promoter, flanking introns, and exons of AICDA, BTK, CD40, CD154, TACI, and SH2D1A in all 19 patients. For NEMO, we observed an intronic variation at position c.1056-6T>C in 2 patients, and a hemizygous missense mutation at c.337G>A resulting in a change from aspartic acid to asparagine at amino acid position 113 in one other patient. Lastly, a heterozygous missense mutation at c.425A>T resulting in a change of aspartic acid to valine at amino acid position 142 was observed in UNG for one patient who had both IgA and IgG deficiency.
Discussion
In these studies, we demonstrate that hypogammaglobulinemia of the uninvolved immunoglobulins (IgA, IgG) is a common finding in patients with WM. patients was 63.3%, 58.0% and 49.3%, which is similar to the incidence reported among patients with chronic lymphocytic leukemia, 6,7 but higher than that reported in other indolent lymphomas wherein the incidence of IgA and IgG hypogammaglobulinemia ranges from 10-20%. 7 The incidence of IgA and/or IgG hypogammaglobulinemia observed in this study also appears higher in comparison to those observed in individuals with IgM monoclonal gammopathy of unknown significance (MGUS), though there has been great variation in the reported incidence (8-35%).
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The inclusion of patients having up to 10% bone marrow disease involvement, who are now considered to have WM based on consensus diagnostic criteria, may account for the higher incidence of IgA and/or IgG hypogammaglobulinemia observed in Kyle et al17 series in which up to 35% of IgM MGUS patients had IgA and/or IgG hypogammaglobulinemia.
Importantly, in our series of 207 untreated WM patients, was the observation that the presence of IgA and/or IgG hypogammaglobulinemia was unrelated to age, sex, serum IgM levels, degree of bone marrow disease involvement, myelosuppression, absolute lymphocyte count, or prognostic indices including b2-microglobulin levels, and the WM IPSS score. Therefore the presence of IgA and IgG hypogammaglobulinemia is unlikely to be a consequence of disease burden per se. Surprising, a lower incidence of IgA and IgG hypogammaglobulinemia was observed in the presence of adenopathy and splenomegaly, both features which are seen in less than 20% of WM patients. This finding may signify that the pathogenesis for WM patients exhibiting adenopathy/and or splenomegaly may reflect a disease process more in keeping with other indolent non-Hodgkin's lymphomas in whom IgA and/or IgG hypogammaglobulinemia is less common as previously discussed.
The presence of IgA and/or IgG hypogammaglobulinemia was reported to predict for evolution of IgM MGUS to WM in the Kyle et al series. 16 While the presence of IgA and IgG hypogammaglobulinemia per se was not associated with disease progression, WM patients in this series who were initially placed on watch and wait and who ultimately progressed demonstrated lower median IgA and IgG levels. Striking was also the observation that the presence of IgA and/or IgG hypogammaglobulinemia did not predict for recurrent infections. Comparison of the median IgA and IgG levels for patients with and without recurrent infections, as well as the presence of IgA and/or IgG hypogammaglobulinemia using our institutional cutoffs did not show any significant differences. The use of lower IgA (<30 mg/dL) and IgG (IgG <300 mg/dL) cutoffs also did not demonstrate any differences in the incidence of recurrent infections. These results suggest that other immunological and possibly even anatomical differences may contribute to the risk of recurrent infections, particularly for respiratory tract infections. The routine use of intravenous immunoglobulin replacement for WM patients with low IgA and IgG levels should therefore be considered prudently, since low IgA and IgG levels per se do not imply increased infection risk for WM patients, and should be considered in a case by case basis taking into account a patient's infection history as has been advocated in patients with other B-cell malignancies.
